Pulmonary Clinical Trials

1,175 recruitingLast updated: June 17, 2026

There are 1,175 actively recruiting pulmonary clinical trials across 90 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4, Early Phase 1. Top locations include Beijing, Beijing Municipality, China, Philadelphia, Pennsylvania, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Pulmonary Trials at a Glance

1,175 actively recruiting trials for pulmonary are listed on ClinicalTrialsFinder across 6 cities in 90 countries. The largest study group is Not Applicable with 364 trials, with the heaviest enrollment activity in Beijing, Philadelphia, and Boston. Lead sponsors running pulmonary studies include China-Japan Friendship Hospital, AstraZeneca, and Assistance Publique - Hôpitaux de Paris.

Treatments under study

About Pulmonary Clinical Trials

Looking for clinical trials for Pulmonary? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pulmonary trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pulmonary clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 1,175 trials

Recruiting
Not Applicable

Simulation Trial of Telemedical Support for Paramedics

Acute Respiratory FailureEmergenciesCardiopulmonary Arrest+1 more
Boston Medical Center420 enrolled9 locationsNCT06441760
Recruiting
Not Applicable

Mindful-Breath for People With COPD

MindfulnessChronic Obstructive Pulmonary Disease (COPD)Pulmonary Rehabilitation
The University of Hong Kong60 enrolled1 locationNCT07195838
Recruiting

Study of Microbiological Diversity in Exhaled Air in COPD and Free of COPD

Chronic Obstructive Pulmonary Disease
Centre Hospitalier Intercommunal Creteil240 enrolled1 locationNCT05437198
Recruiting

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

Pulmonary Disease, Chronic Obstructive
AstraZeneca2,000 enrolled7 locationsNCT06712563
Recruiting
Not Applicable

Ventilation/Perfusion PET/CT With Galligas and 68Ga-MAA for Regional Lung Function Assessment After Pulmonary Embolism

DyspneaPulmonary Embolism
University Hospital, Brest32 enrolled1 locationNCT05103670
Recruiting

Data Clustering Study With Artificial Intelligence and Phenotyping of Patients With Acute Pulmonary Embolism

Pulmonary Embolism
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer2,500 enrolled1 locationNCT06183944
Recruiting
Not Applicable

Impact on Quality of Life With Pulmonary RehAbilitation After Pulmonary eMBOlism: RAMBO Study

Pulmonary EmbolismQuality of Life and Dyspnea
University Hospital, Brest112 enrolled6 locationsNCT05015153
Recruiting

Study of Lung Proteins in Patients With Pneumonia

Pulmonary DiseasePneumoniaLung Disease
National Institutes of Health Clinical Center (CC)750 enrolled1 locationNCT00077909
Recruiting

Role of Genetic Factors in the Development of Lung Disease

AsthmaCystic FibrosisPulmonary Fibrosis+2 more
National Heart, Lung, and Blood Institute (NHLBI)3,500 enrolled2 locationsNCT00001532
Recruiting

Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

Pulmonary DiseasePulmonary Hypertension
National Institutes of Health Clinical Center (CC)270 enrolled1 locationNCT01730092
Recruiting

DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Pleuropulmonary BlastomaCystic NephromaNasal Chondromesenchymal Hamartoma+2 more
National Cancer Institute (NCI)1,500 enrolled2 locationsNCT01247597
Recruiting
Not Applicable

Residual Pulmonary Vascular Obstruction Index Computed With Ventilation/Perfusion SPECT/CT Imaging to Predict the Risk of Venous Thromboembolism Recurrence in Patients With Pulmonary Embolism (PRONOSPECT)

Venous ThromboembolismPulmonary Embolism
University Hospital, Brest665 enrolled13 locationsNCT06372730
Recruiting
Phase 3

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled215 locationsNCT07190209
Recruiting

Innate Immunity in COPD

Chronic Obstructive Pulmonary Disease
University of Edinburgh189 enrolled2 locationsNCT05743582
Recruiting
Phase 3

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled213 locationsNCT07190222
Recruiting
Phase 4

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease
Sanofi218 enrolled68 locationsNCT07053423
Recruiting

Study That Will Evaluate the Brazilian Population With COPD.

COPD, Chronic Obstructive Pulmonary Disease
AstraZeneca693 enrolled10 locationsNCT06780046
Recruiting
Phase 2Phase 3

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI)189 enrolled249 locationsNCT05058651
Recruiting
Phase 3

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC815 enrolled119 locationsNCT07218029
Recruiting
Not Applicable

Early Exercise-Based Rehabilitation in Patients Hospitalized for Acute Pulmonary Embolism

Quality of Life (QOL)Exercise TherapyAnxiety Depression+7 more
Insel Gruppe AG, University Hospital Bern160 enrolled6 locationsNCT07143539